Iswarya Fertility Center, headquartered in Chennai, has raised over Rs 350 crore (about $37 million) in growth funding, led by healthcare investment firm OrbiMed Asia, according to an announcement.
The company said it will use the funds to set up new centres in existing and underserved markets, strengthen its clinical infrastructure, invest in digital capabilities, and expand its embryology talent pipeline.
“Our focus over the next phase is clear: deepen our pan-India presence, enter underserved geographies and keep raising the bar on clinical outcomes,” Dr. Arun Muthuvel, managing director at Iswarya Fertility Center, said in the media statement.
Established in 1986, Iswarya is today among southern India’s largest fertility networks, with over 85 centres spread across eight states. It claims to have served more than 300,000 couples over the past four decades.
The investment comes at a time when India’s total fertility rate has fallen below the replacement level of 2.1, which is considered necessary to maintain long-term population stability.
According to the Sample Registration System (SRS) Statistical Report 2024, India’s total fertility rate has declined to 1.9.
Today, couples are increasingly looking towards fertility treatments as changing lifestyles and other factors contribute to rising infertility rates.
Among other developments in the sector, Indira IVF saw a majority stake acquired by BPEA EQT, a deal first reported by DealStreetAsia.
OrbiMed, based in the US, typically focuses on investments in biopharmaceuticals, medical devices, diagnostics, and healthcare services. Its India portfolio includes companies such as Advanced Enzymes, Suraksha Diagnostics, and Arcatron Mobility.
